Summit Healthcare Acquisition Corp.
SMIHW
NASDAQ Capital Market0.21
USD
+0.01
- -
CIK
0001839185
Return %
Stock
S&P500
1Y
18.71
18.21
3Y
-83.92
63.29
5Y
-83.92
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001839185
- Similar Companies
- Business
- Summit Healthcare Acquisition Corp. (NASDAQ:SMIHW) operates as a blank check company, or special purpose acquisition company (SPAC), whose sole purpose focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, particularly targeting opportunities in the healthcare sector; it offers no current products or services beyond this acquisition mandate. Founded in 2020 and headquartered at Unit 1101, 11th Floor, 1 Lyndhurst Tower, 1 Lyndhurst Terrace, Central, Hong Kong, the company went public via IPO in June 2021, raising approximately $200 million, with units, Class A ordinary shares, and warrants trading under tickers SMIHU, SMIH, and SMIHW, respectively. In its major strategic development, Summit completed a business combination with YishengBio Co., Ltd. (YS Biopharma), a global biopharmaceutical firm specializing in innovative vaccines and biologics such as PIKA-adjuvanted rabies and COVID-19 vaccines, on March 16, 2023; the transaction valued YS Biopharma at an implied enterprise value of $849 million, delivered about $36 million in gross proceeds (assuming redemptions), and resulted in the combined entity trading as YS Biopharma Co., Ltd. under new Nasdaq symbols YS and YSBPW. The SMIHW warrants persist as remnants of the original SPAC structure post-merger, with no reported additional partnerships, funding rounds, acquisitions, or operational shifts for Summit itself in 2024 or 2025. Summit conducts its activities on a global basis, with a focus on healthcare targets across regions including Asia, the United States, Singapore, the United Arab Emirates, and the Philippines via its merger partner.